Index -
P/E -
EPS (ttm) -2.25
Insider Own 63.15%
Shs Outstand 11.82M
Perf Week 1.42%
Market Cap 23.24M
Forward P/E -
EPS next Y -1.38
Insider Trans 0.00%
Shs Float 5.99M
Perf Month -5.92%
Income -33.95M
PEG -
EPS next Q -0.55
Inst Own 18.48%
Short Float / Ratio 2.15% / 0.30
Perf Quarter -39.41%
Sales 48.40M
P/S 0.48
EPS this Y 13.87%
Inst Trans -0.12%
Short Interest 0.13M
Perf Half Y -12.27%
Book/sh -1.36
P/B -
EPS next Y 32.93%
ROA -64.54%
Target Price 12.00
Perf Year -78.81%
Cash/sh 0.57
P/C 2.50
EPS next 5Y -
ROE -775.14%
52W Range 1.10 - 9.01
Perf YTD -66.35%
Dividend -
P/FCF -
EPS past 5Y -21.70%
ROI -372.57%
52W High -84.13%
Beta -0.04
Dividend % -
Quick Ratio 0.63
Sales past 5Y 6.05%
Gross Margin 35.86%
52W Low 30.00%
ATR 0.21
Employees 164
Current Ratio 0.84
Sales Q/Q -18.53%
Oper. Margin -49.98%
RSI (14) 50.21
Volatility 13.73% 16.44%
Optionable No
Debt/Eq -
EPS Q/Q 5.13%
Profit Margin -70.13%
Rel Volume 0.14
Prev Close 1.36
Shortable Yes
LT Debt/Eq -
Earnings Aug 14 AMC
Payout -
Avg Volume 429.46K
Price 1.43
Recom 1.00
SMA20 5.60%
SMA50 -11.33%
SMA200 -46.07%
Volume 58,339
Change 5.15%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-02-20 Initiated
Truist
Buy
$20
Nov-02-20 Initiated
Piper Sandler
Overweight
$20
Nov-02-20 Initiated
Cowen
Outperform
$20
Nov-02-20 Initiated
Cantor Fitzgerald
Overweight
$20
Sep-20-23 08:30AM
Sep-19-23 08:36AM
Sep-18-23 04:08PM
Sep-08-23 08:30AM
Sep-06-23 04:05PM
08:30AM
Loading…
Aug-30-23 08:30AM
Aug-21-23 09:42AM
Aug-15-23 05:21AM
(Thomson Reuters StreetEvents) +6.72%
Aug-14-23 04:05PM
Jul-31-23 04:05PM
Jul-26-23 03:29PM
(American City Business Journals)
Jul-17-23 04:05PM
Jul-13-23 04:30PM
May-19-23 01:45PM
08:15AM
08:17AM
Loading…
May-13-23 08:17AM
May-11-23 09:58AM
05:51AM
(Thomson Reuters StreetEvents)
May-10-23 04:05PM
May-03-23 04:05PM
10:42AM
(Thomson Reuters StreetEvents)
Apr-20-23 04:30PM
Apr-17-23 06:11AM
Apr-05-23 09:55AM
Mar-27-23 06:26AM
Mar-23-23 06:08AM
(Thomson Reuters StreetEvents) +17.65%
Mar-22-23 04:01PM
08:30AM
Mar-20-23 12:01PM
08:00AM
04:05PM
Loading…
Mar-15-23 04:05PM
Feb-27-23 08:15AM
Jan-31-23 08:00AM
Jan-26-23 12:00PM
09:40AM
Jan-21-23 09:58AM
Jan-09-23 08:15AM
Dec-15-22 08:00AM
Dec-10-22 07:38AM
Dec-01-22 09:04AM
Nov-30-22 04:08PM
Nov-21-22 04:05PM
Nov-16-22 06:00AM
Nov-14-22 05:25PM
04:01PM
Nov-07-22 04:05PM
07:40AM
Oct-25-22 09:47AM
Oct-24-22 08:00AM
Oct-18-22 04:05PM
Oct-11-22 04:35PM
07:44AM
Aug-26-22 09:00AM
Aug-17-22 04:05PM
Aug-16-22 01:53PM
(American City Business Journals)
Aug-14-22 10:16AM
Aug-11-22 04:05PM
03:09PM
(American City Business Journals)
Aug-10-22 06:56PM
Aug-09-22 05:58PM
Jul-28-22 04:05PM
Jul-20-22 09:40AM
Jun-27-22 04:15AM
Jun-21-22 04:05PM
Jun-01-22 08:50AM
May-09-22 05:25PM
04:05PM
May-02-22 08:21AM
Apr-25-22 04:05PM
Apr-12-22 04:05PM
Apr-04-22 08:00AM
Mar-31-22 06:50PM
Mar-11-22 08:30AM
Mar-07-22 06:40AM
(Simply Wall St.) -15.89%
Mar-04-22 09:28AM
Mar-03-22 06:25PM
04:01PM
Feb-23-22 04:01PM
Feb-17-22 04:01PM
Feb-14-22 12:00PM
09:40AM
Jan-18-22 08:45AM
Jan-11-22 10:00AM
Dec-27-21 04:01PM
Dec-08-21 05:31PM
Dec-06-21 06:59AM
Nov-15-21 04:05PM
Nov-09-21 05:25PM
04:01PM
Nov-02-21 03:02PM
Oct-26-21 08:30AM
Oct-25-21 04:01PM
Sep-15-21 04:05PM
Aug-31-21 04:05PM
Aug-15-21 03:05AM
Aug-09-21 04:01PM
Jul-26-21 04:01PM
Jun-30-21 09:34AM
Jun-10-21 01:30AM
Jun-07-21 08:00AM
Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women's Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women's Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mills C Randal PRESIDENT AND CEO Apr 27 Option Exercise 0.00 44,947 0 48,008 Apr 28 05:31 PM Birchview Capital, LP 10% Owner Mar 27 Buy 1.59 10,000 15,870 1,655,184 Mar 27 04:17 PM Birchview Capital, LP 10% Owner Mar 24 Buy 1.35 20,000 27,078 1,645,184 Mar 27 04:17 PM Birchview Capital, LP 10% Owner Mar 23 Buy 1.49 110,000 164,010 1,625,184 Mar 27 04:17 PM Englese Thomas CHIEF COMMERCIAL OFFICER Mar 09 Sale 4.30 289 1,243 17,917 Mar 09 09:18 PM Englese Thomas CHIEF COMMERCIAL OFFICER Mar 08 Option Exercise 0.00 937 0 18,206 Mar 09 09:18 PM Ferguson Matthew CHIEF FINANCIAL OFFICER Mar 08 Option Exercise 0.00 1,287 0 46,504 Mar 09 09:11 PM Colpman David Director Dec 15 Buy 3.90 3,098 12,082 3,098 Dec 16 04:46 PM Makes Brigid Director Dec 09 Buy 3.65 2,000 7,300 2,000 Dec 12 05:08 PM Birchview Capital, LP 10% Owner Dec 08 Buy 3.79 13,061 49,518 1,515,184 Feb 13 07:01 PM Birchview Capital, LP 10% Owner Dec 07 Buy 3.58 44,000 157,520 1,502,123 Feb 13 07:01 PM HighCape Capital, L.P. Director Dec 05 Buy 4.75 735,000 3,491,250 5,597,604 Dec 07 04:31 PM Ferguson Matthew CHIEF FINANCIAL OFFICER Dec 05 Buy 4.65 22,000 102,220 45,217 Dec 05 08:44 PM Ferguson Matthew CHIEF FINANCIAL OFFICER Dec 02 Buy 4.03 6,000 24,180 23,217 Dec 05 08:44 PM Birchview Capital, LP 10% Owner Dec 01 Buy 4.75 40,000 190,000 1,458,123 Feb 13 07:01 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite